Lung Tissue Engineering

肺组织工程

• 批准号: 8206739
• 负责人: LAURA E NIKLASON
• 金额: $ 62.05万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-15 至 2013-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8206739
• 关键词: 3-Dimensional; Accounting; Address; Adhesions; Adhesives; Adult; Air; Alveolar; Alveolus; American Lung Association; Anatomy; Architecture; Area; Autologous; Biology; Biomimetics; Bioreactors; Bladder; Blood; Blood Circulation; Blood Vessels; Bone Marrow; Breathing; Bronchi; Carbon Dioxide; Cartilage; Cell Differentiation process; Cell Therapy; Cells; Cessation of life; Characteristics; Chronic Obstructive Airway Disease; Chronic lung disease; Clinical; Clinical Trials; Complex; Connective Tissue; Data; Detergents; Differentiation and Growth; Effectiveness; Elements; Endothelium; Engineering; Environment; Epithelial; Epithelial Cells; Epithelium; Event; Exposure to; Fibroblast Growth Factor 2; Future; Gases; Glean; Goals; Growth; Growth and Development function; Harvest; Human; In Vitro; Infection; Intervention; Knowledge; Liquid substance; Location; Lung; Lung Transplantation; Lung diseases; Malignant neoplasm of lung; Measurement; Mechanics; Microscopic; Mission; Mucous body substance; Natural regeneration; Neonatal; Nutrient; Organ; Oxygen; Pathologist; Patients; Perfusion; Permeability; Physiological; Population; Procedures; Production; Property; Rattus; Regenerative Medicine; Research Personnel; Resected; Rodent Model; Skin; Source; Staging; Stem cells; Sterility; Structure; Structure of parenchyma of lung; Support System; Surface; System; Technology; Testing; Tissue Engineering; Tissues; Trachea; Tretinoin; Universities; Ursidae Family; Vascular Graft; Vascular Permeabilities; Work; base; cell growth; embryonic stem cell; improved; in utero; in vivo; induced pluripotent stem cell; insight; lung injury; mortality; novel; pressure; public health relevance; remediation; repaired; scaffold; shear stress; skills; stem cell biology; success; surfactant; tissue regeneration; vascular tissue engineering

DESCRIPTION (provided by applicant): Lung diseases, including lung cancer and chronic lung diseases such as chronic obstructive pulmonary disease, together account for some 280,000 deaths annually (American Lung Association). Contributing to this mortality is the fact that remediation of all forms of lung disease is hampered by the limited ability of lung to regenerate. Hence, lung tissue that is damaged by degeneration or infection, or lung tissue that is surgically resected, is not functionally replaced in vivo. Currently, the only way to replace lung tissue is to perform lung transplantation, an expensive procedure that is achieves only a 10% survival at 10 years, and one that is hampered by a severe shortage of organs. Over the past 3 years, we have worked to address some fundamental challenges in lung tissue engineering. In order to produce a lung scaffold that has suitable geometry and mechanics for lung regeneration, we have developed technologies to decellularize entire lung tissues. We have shown that these acellular lung matrices retain the gross mechanical properties of the original lung tissues, and provide outstanding support for the adhesion and growth of epithelial and vascular cells. We have developed a novel, "biomimetic" bioreactor that provides for long-term sterile lung culture, circulation of nutrient medium through the lung vascular compartment, and "breathing" of nutrient medium into the airway. As a cell source to repopulate the acellular lung matrix, we have utilized syngeneic neonatal rat lung cells, as these cells show significant potential for growth inside the developing lung. We have made substantial and exciting progress in this work, and have shown the feasibility of regenerating many characteristics of lung tissue, but there remain several important issues that must be studied and addressed before the functionality of such lung tissues can be tested in vivo. Most fundamentally, in order to exchange gas, the lung must comprise sufficient alveolar diffusional surface area, must be populated with functional and differentiated epithelial cell subsets at correct anatomic locations in the alveoli and elsewhere, and must be invested with a functional microvasculature that withstands physiological perfusion pressures and does not leak fluid into the alveolar compartment. In this proposal, we will study and refine the lung tissue engineering system in order to address each of these issues and advance the central mission of functional lung regeneration, which is the capacity for effective gas exchange. We hypothesize that the acellular lung matrix, when suitably re-populated with lung epithelium and vascular cells, will support the growth and differentiation of these cells and will produce a tissue that is effective for gas exchange, based upon in vitro measurements. PUBLIC HEALTH RELEVANCE: Lung diseases, including lung cancer and chronic lung diseases such as chronic obstructive pulmonary disease, together account for some 280,000 deaths annually. Over the past 3 years, we have worked to address some fundamental challenges in lung tissue engineering in order to provide lung tissue replacements for patients with lung disease. We hypothesize that an acellular lung matrix, when suitably re-populated with lung epithelium and vascular cells, will support the growth and differentiation of these cells and will produce a tissue that is effective for functional gas exchange.

描述（由申请人提供）：肺部疾病，包括肺癌和慢性肺部疾病，如慢性阻塞性肺病，每年共造成约280，000例死亡（美国肺脏协会）。导致这种死亡率的原因是，所有形式的肺部疾病的补救都受到肺部再生能力有限的阻碍。因此，因变性或感染而受损的肺组织或手术切除的肺组织在体内不会被功能性替代。目前，替代肺组织的唯一方法是进行肺移植，这是一种昂贵的手术，10年生存率仅为10%，并且由于器官严重短缺而受到阻碍。 在过去的3年里，我们一直致力于解决肺组织工程中的一些基本挑战。为了生产具有适合肺再生的几何形状和力学的肺支架，我们开发了使整个肺组织脱细胞的技术。我们已经证明，这些脱细胞肺基质保留了原始肺组织的总体机械性能，并为上皮细胞和血管细胞的粘附和生长提供了出色的支持。我们已经开发了一种新型的“仿生”生物反应器，其提供长期无菌肺培养、营养培养基通过肺血管隔室的循环以及营养培养基“呼吸”到气道中。作为一种细胞来源，以重新填充脱细胞肺基质，我们已经利用同基因新生大鼠肺细胞，因为这些细胞显示出显着的潜力，在发育中的肺内生长。我们在这项工作中取得了实质性的和令人兴奋的进展，并已显示出再生肺组织的许多特征的可行性，但仍有几个重要的问题，必须研究和解决之前，这样的肺组织的功能可以在体内进行测试。最基本的是，为了交换气体，肺必须包括足够的肺泡扩散表面积，必须在肺泡和其他地方的正确解剖位置处填充有功能性和分化的上皮细胞亚群，并且必须具有承受生理灌注压力并且不将流体泄漏到肺泡隔室中的功能性微脉管系统。在本提案中，我们将研究和完善肺组织工程系统，以解决这些问题中的每一个，并推进功能性肺再生的中心使命，这是有效的气体交换能力。基于体外测量，我们假设，当用肺上皮细胞和血管细胞适当地重新填充时，脱细胞肺基质将支持这些细胞的生长和分化，并将产生对气体交换有效的组织。 公共卫生相关性：包括肺癌和慢性阻塞性肺病等慢性肺病在内的肺部疾病每年共造成约28万人死亡。在过去的3年里，我们一直致力于解决肺组织工程中的一些基本挑战，以便为肺部疾病患者提供肺组织替代物。我们假设，当用肺上皮细胞和血管细胞适当地重新填充时，脱细胞肺基质将支持这些细胞的生长和分化，并将产生对功能性气体交换有效的组织。